AVIR
Atea Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$446.55M
P/E Ratio
—
EPS
$-1.94
Beta
0.16
52W High
$6.45
52W Low
$2.46
50-Day MA
$5.47
200-Day MA
$3.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $192.18M |
| Gross Profit (TTM) | $-146.53M |
| EBITDA | $-178.98M |
| Operating Margin | 0.00% |
| Return on Equity | -44.30% |
| Return on Assets | -28.70% |
| Revenue/Share (TTM) | $2.31 |
| Book Value | $3.52 |
| Price-to-Book | 1.62 |
| Price-to-Sales (TTM) | 1.55 |
| EV/Revenue | 58.97 |
| EV/EBITDA | -260.47 |
| Quarterly Earnings Growth (YoY) | 264.10% |
| Quarterly Revenue Growth (YoY) | 295.20% |
| Shares Outstanding | $80.03M |
| Float | $59.45M |
| % Insiders | 13.36% |
| % Institutions | 76.58% |
Historical Volatility
HV 10-Day
37.17%
HV 20-Day
37.51%
HV 30-Day
44.66%
HV 60-Day
48.70%
HV Rank
46.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($8.83 target)
2
Buy1
HoldData last updated: 4/29/2026